Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-06T13:12:23.562Z Has data issue: false hasContentIssue false

9 - Opening the dam: patent pools, innovation and access to essential medicines

Published online by Cambridge University Press:  04 August 2010

Thomas Pogge
Affiliation:
Yale University, Connecticut
Matthew Rimmer
Affiliation:
Australian National University, Canberra
Kim Rubenstein
Affiliation:
Australian National University, Canberra
Get access

Summary

Introduction

It would be difficult to conceive of a world where the medicines necessary to treat the world's most prevalent diseases were not protected by patents. The patent system is so entrenched in the healthcare industry (particularly in the pharmaceutical sector) and the practice of applying for patents to protect the fruits of biomedical research so ingrained, that anyone involved in the public health innovation cycle of discovery, development and delivery must find a way to traverse the increasingly complex patent landscape. While some countries may be freed from patent fetters if they lack relevant patent legislation or if relevant patents have not been filed or granted, the number of countries in this category is ever decreasing and those that remain untouched by patent monopolies are likely to lack the capacity to undertake research or to manufacture medicines. Yet it has been explicitly stated in some of the highest international policy forums that intellectual property rights do not and should not prevent member states from taking measures to protect public health. The Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (‘IGWG’) of the World Health Organization (‘WHO’) has stated as much in paragraph 20 of its draft Global Strategy on Public Health. The question that needs to be addressed is how to achieve this end of protecting public health whilst at the same time maintaining the incentive to innovate.

Type
Chapter
Information
Incentives for Global Public Health
Patent Law and Access to Essential Medicines
, pp. 235 - 262
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×